MedPath

扬子江药业集团江苏紫龙药业有限公司

Ownership
-
Established
2011-12-06
Employees
-
Market Cap
-
Website
http://zilong.yangzijiang.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

19

NMPA:19

Drug Approvals

Ganirelix Injection

Product Name
醋酸加尼瑞克注射液
Approval Number
国药准字H20249134
Approval Date
Oct 22, 2024
NMPA

Acetylcysteine Solution for Inhalation

Product Name
吸入用乙酰半胱氨酸溶液
Approval Number
国药准字H20243641
Approval Date
Apr 30, 2024
NMPA

Tedizolid Phosphate Tablets

Product Name
磷酸特地唑胺片
Approval Number
国药准字H20243454
Approval Date
Apr 7, 2024
NMPA

Roxatidine Acetate Hydrochloride For Injection

Product Name
注射用盐酸罗沙替丁醋酸酯
Approval Number
国药准字H20233994
Approval Date
Aug 1, 2023
NMPA

Levornidazole Disodium Phosphate for Injection

Product Name
新锐
Approval Number
国药准字H20227110
Approval Date
Aug 30, 2022
NMPA

Levornidazole Disodium Phosphate for Injection

Product Name
新锐
Approval Number
国药准字H20227072
Approval Date
May 31, 2022
NMPA

Dapoxetine Hydrochloride Tablets

Product Name
盐酸达泊西汀片
Approval Number
国药准字H20213932
Approval Date
Dec 14, 2021
NMPA

Rupatadine Fumarate Tablets

Product Name
富马酸卢帕他定片
Approval Number
国药准字H20173112
Approval Date
Dec 6, 2021
NMPA

Nalbuphine Hydrochloride Injection

Product Name
盐酸纳布啡注射液
Approval Number
国药准字H20213884
Approval Date
Nov 24, 2021
NMPA

Moxifloxacin Hydrochloride Tablets

Product Name
盐酸莫西沙星片
Approval Number
国药准字H20213553
Approval Date
Jun 29, 2021
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.